Despite the introduction of a vaccine, newborns in New Zealand still have a high rate of pneumococcal disease Maternal vaccination could help protect these infants

Despite the introduction of pneumococcal conjugate vaccine (PCV) in the childhood immunization program in New Zealand, the incidence of invasive pneumococcal disease in neonates (<30 days old) remains relatively high at 6 per 100,000 (versus 2/100,000 in the U.S.). Out of 19 cases in infants <30 days old in this study, 9 (47%) occurred during the first 7 days of life and 6 within the first 48 hours. If proven effective, maternal vaccination would cover 74% to 84% of the serotypes that infected these infants, depending on the vaccine.

Immunization reduced hospitalization disparities for children from ethnic minorities

In New Zealand, Maori and Pacific children have historically suffered high hospitalization rates for invasive pneumococcal disease (IPD), all cause pneumonia (ACP), and otitis media. Following the introduction of conjugate vaccines in the country, Maori and Pacific children’s rates of admission for IPD dropped by 79% and 67%, respectively, while significant reductions in ACP and otitis media admissions were also noted, resulting in reductions in disparities for these populations.